Durect corp

Financial Times Close.

DURECT harnesses epigenetic modulation to treat serious and life-threatening conditions, including acute organ injury and cancer. Many types of acute organ injuries and cancers are associated with dysregulation of the epigenome, such as DNA methylation. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth. Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies. Brown, President and Chief.

Durect corp

.

Our first epigenetic modulator, larsucosterol, durect corp, may have the potential to save the lives of durect corp with AH and become a new standard of care, based on outcomes from clinical trials to date. But opting out of some of these cookies may have an effect on your browsing experience.

.

The pre-funded warrants and the accompanying warrants will be immediately exercisable. The pre-funded warrants do not expire and the accompanying warrants will expire five years from the date of issuance. The closing of the Offering is expected to occur on or about February 8, , subject to customary closing conditions. DURECT intends to use the net proceeds of the Offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to, and describing the terms of, the Offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of , relating to: the Offering, statements regarding the completion of the Offering and the expected use of proceeds from the Offering, Fast Track Designation of larsucosterol, the potential to develop larsucosterol for AH, NASH or other indications, the commercialization of POSIMIR by Innocoll, and the potential benefits, if any, of our product candidates. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance.

Durect corp

Brown , D. We look forward to entering discussions with the U. We also plan to discuss the design of a potential registrational Phase 3 trial using mortality as the primary endpoint.

Buyee zenmarket

But opting out of some of these cookies may have an effect on your browsing experience. Brown, President and Chief. Short selling activity Low. Short lived cookies used by Motomo Analytics to temporarily store data for the visit. This cookie is used by the website's WordPress theme. Clin Epigenetics. Our first epigenetic modulator, larsucosterol, may have the potential to save the lives of patients with AH and become a new standard of care, based on outcomes from clinical trials to date. Analytical cookies are used to understand how visitors interact with the website. The cookie is used to store the user consent for the cookies in the category "Analytics". Alcohol-Associated Hepatitis AH. Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. It allows the website owner to implement or change the website's content in real-time. This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.

The closing of the Offering is expected to occur on or about July 21, , subject to customary closing conditions. DURECT intends to use the net proceeds of the Offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Cookie Duration Description c 6 months 2 days This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities. Our first epigenetic modulator, larsucosterol, may have the potential to save the lives of patients with AH and become a new standard of care, based on outcomes from clinical trials to date. Average volume The cookie is used to store the user consent for the cookies in the category "Performance". Analytical cookies are used to understand how visitors interact with the website. Manage cookie consent. All content on FT. You can manage and withdraw your consent at any time using our cookie consent tool found here in Cookie Settings. The cookies is used to store the user consent for the cookies in the category "Necessary".